In addition, a subgroup difference between inv(16) and t(8,21) AML for OS was observed as P = 0.12 and I2 = 58% in the random-effects model and P = 0.03 and I2 = 78% in the fixed-effects model, which indicated that, as with the relapse rate, OS of CBF-AML should be evaluated in subgroups with in terms of the KIT mutations. Here, CEBPZ is linked to acute myeloid leukemia.